Clinical Trial

CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC

Study acronym: CHOICE
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 13, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2026-02-09; most recent amendment 2026-07-10.
Status change: Not Yet Recruiting → Recruiting 2026-03-24
Trial Details
NCT Number NCT07413757
Lead Sponsor AstraZeneca
Conditions Non-Small Cell Lung Cancer
Enrollment 590 participants
Start Date 2026-03-02
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-13